Vioxx, a Blockbuster Recall
MBA 520- Ethics & Leadership in a Global Environment
Professor Joe Limas
AbstractVioxx became Merck’s most profitable drug in the early 2000’s. The drug was a blockbuster in terms of sales, profit and prescriptions issued. Vioxx also was recalled by Merck and taken off the market in 2004 due to adverse cardiac events CITATION Law14 \l 1033 (Lawerence & Weber, 2014). The drug recall has been studied and discussed as controversial due to the clinical data Merck had in its studies, the FDA quick approval, lobbyist efforts in Washington, and the enormous marketing effort by Merck. The system in place allowed thousands of individuals that where prescribed Vioxx to have adverse cardiac efforts and take risks that were not disclosed. The recall of the drug was ultimately the correct decision, but it was too late. Vioxx caused thousands of patients to have health problems. TABLE OF CONTENTS TOC \o "1-3" \h \z \u Abstract PAGEREF _Toc386564548 \h iiTABLE OF CONTENTS PAGEREF _Toc386564549 \h iiiINTRODUCTION PAGEREF _Toc386564550 \h 1References4
INTRODUCTIONVioxx had been one of the most successful drugs in history. The drug was a maintenance medication for painful conditions such as arthritis. Maintenance drugs became highly desired by pharmaceutical companies due too long term profitability resulting from no cure CITATION Law14 \l 1033 (Lawerence & Weber, 2014). Vioxx was prescribed to over twenty million people in the United States. Merck posted a seven billion dollar profit in a single year from Vioxx CITATION Law14 \l 1033 (Lawerence & Weber, 2014). Within six years from its release, Vioxx was recalled from the market due to adverse health defects. Merck voluntarily recalled the product resulting from post marketing safety studies. Do you believe that Merck acted in a socially responsible and ethical manner with regard to Vioxx? Why or why not? In your answer, please...
References: BIBLIOGRAPHY Lawerence, A., & Weber, J. (2014). Business and Society: Stakeholders, Ethics, Public Policy (14th ed.). New York: McGraw Hill.
Phua, K. L., & Achike, F. I. (2007). Vioxxx and other pharmaceutical products withdrawals: ethical issues in ensuring the integrity of drug and medical device research, development and commercialization. Clinical Ethics, 2(3), 155-162. doi:10.1258/147775007781870029
Strom, B. L. (2006, May 3). How the US Drug Safety System Should Be Changed. JAMA, 295(17), 2072-2075. doi:10.1001/jama.295.17.2072
Please join StudyMode to read the full document